← Eichor
Study identifier: NCT07425821 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Condition: Marburg Virus Disease  ·  Sponsor: International AIDS Vaccine Initiative

PhasePhase 1
Planned participants112
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersYes

About this study

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

This description comes directly from the study's public registry record.

Talk to the study team

Johannes Beeslaar, MD  ·  212-328-7459  ·  JBeeslaar@iavi.org

Always discuss trial participation with your own doctor first.

Locations (2)

George Washington UniversityWashington D.C., District of Columbia, United StatesRecruiting
Johnson County Clin-TrialsLenexa, Kansas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07425821